Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.
Cohan S, Gervasi-Follmar T, Kamath A, Kamath V, Chen C, Smoot K, Baraban E, Edwards K. Cohan S, et al. Among authors: kamath v. Mult Scler J Exp Transl Clin. 2021 Dec 16;7(4):20552173211066588. doi: 10.1177/20552173211066588. eCollection 2021 Oct. Mult Scler J Exp Transl Clin. 2021. PMID: 34950502 Free PMC article.
Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases.
Hemond CC, Bakshi R, Tauhid S, Sarrosa R, Ryan M, Kamath V, Thomas J, Edwards KR. Hemond CC, et al. Among authors: kamath v. J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211033047. doi: 10.1177/23247096211033047. J Investig Med High Impact Case Rep. 2021. PMID: 34308699 Free PMC article.
A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Edwards KR, Kamath A, Button J, Kamath V, Mendoza JP, Zhu B, Plavina T, Woodward C, Penner N. Edwards KR, et al. Among authors: kamath v. Mult Scler Relat Disord. 2021 Jun;51:102861. doi: 10.1016/j.msard.2021.102861. Epub 2021 Feb 24. Mult Scler Relat Disord. 2021. PMID: 33773271
COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections.
Jakimovski D, Zakalik K, Awan S, Kavak KS, Pennington P, Hojnacki D, Kolb C, Lizarraga AA, Eckert SP, Sarrosa R, Vineetha K, Edwards K, Weinstock-Guttman B. Jakimovski D, et al. Among authors: vineetha k. Vaccines (Basel). 2022 Apr 28;10(5):695. doi: 10.3390/vaccines10050695. Vaccines (Basel). 2022. PMID: 35632451 Free PMC article.
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.
Cohan SL, Edwards K, Lucas L, Gervasi-Follmar T, O'Connor J, Siuta J, Kamath V, Garten L, Chen C, Thomas J, Smoot K, Kresa-Reahl K, Spinelli KJ. Cohan SL, et al. Among authors: kamath v. Mult Scler J Exp Transl Clin. 2019 Jan 16;5(1):2055217318824618. doi: 10.1177/2055217318824618. eCollection 2019 Jan-Mar. Mult Scler J Exp Transl Clin. 2019. PMID: 30729028 Free PMC article.